Evidenzbasierte Entscheidungen statt Tunnelblick
Berichte über seltene schwere Komplikationen im Zusammenhang mit der Verwendung des „Vaxzevria“-Impfstoffes von AstraZeneca haben zu einer erheblichen Verunsicherung der Impflinge geführt. Dazu schreibt das renommierte „Winton Centre for Risk and Evidence Communication“ der Universität Cambridge (Pr...
Main Authors: | Dr. Josef Leiter, Peter Stegmaier |
---|---|
Format: | Article |
Language: | deu |
Published: |
eRelation AG
2021-06-01
|
Series: | Monitor Versorgungsforschung |
Subjects: | |
Online Access: | https://www.monitor-versorgungsforschung.de/Abstracts/Kurzfassungen-2021/mvf-03-21/MVF0321_Winton-Centre |
Similar Items
-
The Most Common Side Effects of AstraZeneca COVID-19 Vaccine among Saudi Arabian Population: A Systematic Review
by: Jehad A. Aldali, et al.
Published: (2023-06-01) -
The first report of myocarditis followed by AstraZeneca vaccination in Iran
by: Karo Servatyari, et al.
Published: (2022-06-01) -
A Battle against COVID-19: Vaccine Hesitancy and Awareness with a Comparative Study between Sinopharm and AstraZeneca
by: Marian S. Boshra, et al.
Published: (2022-02-01) -
Surveillance of COVID-19 vaccines: A comprehensive analysis of the first immunization drive in Ecuador
by: Andrea Orellana-Manzano, et al.
Published: (2024-03-01) -
Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm
by: Enayat Anvari, et al.
Published: (2022-09-01)